CollPlant Biotechnologies Ltd (CLGN) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

Prices Financial Statements ›Discontinued ›News Ratios Analyst Ratings Insider Transactions SEC Filings Roast Me Breakdown

Balance Sheet ›Income Statement ›Expense Statement ›Cash Flow ›Dividends, Cash Notes ›

Concentration Risk, Percentage Receivables ›Inventory ›Lessee, Operating Lease, Liability, to be Paid, after Year Five Debt ›Class of Warrant or Right, Outstanding Equity ›Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Compensation Related Costs ›Income Taxes ›Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Number of Reportable Segments Accounts Payable, Fair Value Disclosure Termination Loans Purchase Options, Land Acquisitiondate Fair Value Of Total Consideration Transferred Additional Paid in Capital Derivative Instruments and Hedging Activities ›Adjustments For Increase Decrease In Other Liabilities Adjustments For Increase Decrease In Other Operating Payables Adjustments For Increase Decrease In Trade Account Payable Adjustments For Increase Decrease In Trade And Other Payables Applicable Tax Rate Assets Cash Flows From Used In Increases In Operating Capacity Cash Flows From Used In Operations Cash Flows From Used In Operations Before Changes In Working Capital Leases ›Cash Transferred Computer Software Current Assets Current Contract Liabilities Current Liabilities Deferred Income Classified As Current Deferred Income Classified As Noncurrent Description Of Expected Volatility Share Options Granted Description Of Risk Free Interest Rate Share Options Granted Equity Equity And Liabilities Finished Goods Fixtures And Fittings Increase Decrease Through Conversion Of Convertible Instruments Increase Decrease Through Exercise Of Options Increase Decrease Through Exercise Of Warrants Equity Intangible Assets ›Investment Property Issue Of Convertible Instruments Issued Capital Liabilities Longterm Borrowings Motor Vehicles Noncurrent Assets Noncurrent Contract Liabilities Noncurrent Debt Instruments Issued Noncurrent Financial Liabilities Noncurrent Government Grants Noncurrent Liabilities Number Of Instruments Or Interests Issued Or Issuable Shares ›Office Equipment Other Current Payables Other Liabilities Owneroccupied Property Measured Using Investment Property Fair Value Model Par Value Per Share Prepayments Reimbursement Rights At Fair Value Reserve Of Exchange Differences On Translation Retained Earnings Rightofuse Assets Tax Rate Effect From Change In Tax Rate Trade And Other Current Payables Trade And Other Current Payables To Trade Suppliers Transfers Of Research And Development From Entity Related Party Transactions Value Added Tax Payables Vehicles Wages And Salaries Work In Progress

Employee Benefits and Share-based Compensation Share-Based Payment Arrangement ›Adjustments For Share-based Payments Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Increase Decrease Through Share-based Payment Transactions Key Management Personnel Compensation Share-based Payment

Expensed and Capitalized, Amount Disclosure ›

Fair Value Assumptions, Expected Volatility Rate Fair Value Assumptions, Risk Free Interest Rate Fair Value Assumptions, Exercise Price Share Price

CollPlant Biotechnologies Ltd Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

CollPlant Biotechnologies Ltd (CLGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.68% for the 6-month period ending 2024-06-30, per its 6-K filed 2024-08-20.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-08-20

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month	Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month
2024-06-30	4.68% 6-K · filed 2024-08-20
2023-06-30	0.36% 6-K · filed 2024-08-20
2019-12-31		1.60% 20-F · filed 2022-03-24